Detalles de la búsqueda
1.
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Clin Lung Cancer
; 20(2): 74-81.e1, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30528315
2.
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
J Clin Oncol
; 23(11): 2544-55, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15753462
3.
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
J Clin Oncol
; 23(25): 5900-9, 2005 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16043828
4.
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Clin Cancer Res
; 10(19): 6522-7, 2004 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15475439
Resultados
1 -
4
de 4
1
Próxima >
>>